ESMO / ECC Conference Coverage

Verzenio™ (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study

(Yahoo! Finance) Oct 9, 2019 - Verzenio plus fulvestrant significantly extended life to a median of 46.7 months vs. 37.3 months compared to fulvestrant alone. MONARCH 2 showed statistically significant results for women whose disease progressed following endocrine therapy. Overall survival results were consistent across subgroups, including in women with poor prognostic factors – whose cancer quickly returned or spread to their organs, such as liver or lungs. Data presented at European Society for Medical Oncology (ESMO) 2019 Congress in the Presidential Symposium and simultaneously published in JAMA Oncology.

read article

Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019

(Yahoo! Finance) Oct 8, 2019 - Adlai Nortye Ltd. announced today at the European Society for Medical Oncology (ESMO) 2019 Congress the first results from a phase 1b neoadjuvant study of AN0025 (previously known as E7046), an investigational, potentially first in class oral EP4 antagonist.

read article

It May Be Time For Standard Breast Cancer Treatment To Change

(Forbes) Oct 3, 2019 - New trial suggests that doctor's shouldn't wait to add targeted therapy drugs to standard breast cancer treatment. Results from a clinical trial show that adding ribociclib, a targeted therapy drug, to the standard treatment plan for women with advanced hormone-receptor positive/HER2- breast cancer helps patients live longer and better quality lives. The researchers involved now believe the drug should be the first line of treatment for patients with this very common form of breast cancer.

read article

ESMO 2019 Makes For A Disappointing Read-Across To Biotech

(Vantage) Oct 2, 2019 - An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.

read article

First Prostate Cancer Therapy to Target Genes Delays Cancer Progression

(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, according to a large, international phase 3 trial.

read article

Experimental Prostate Cancer Therapy Delays Disease In 'Landmark' Trial

(CNN) Sept 30, 2019 - An experimental prostate cancer therapy may change the way patients are treated for the second-deadliest cancer in men. In a "landmark" phase III clinical trial, presented at the European Society of Medical Oncology conference in Barcelona on Monday, the drug olaparib was shown to be safe and effective in delaying the progression of disease in men with both metastatic castrate-resistant prostate cancer and mutations in their homologous recombination repair, or HRR, genes.

read article

Netherlands Drug Repurposing, Tumor Profiling Trial Results Reported at ESMO

(Precision Oncology News) Sept 30, 2019 - Two genomics-centered trials in the Netherlands — the Center for Personalized Cancer Treatment (CPCT-02) and Drug Rediscovery Protocol (DRUP) — are demonstrating the potential for finding tumor genomic features that may guide treatment for advanced cancer patients, even as experts continue working on strategies for interpreting, evaluating, and communicating such findings in a clinical context. During a session on the genomic characterization of cancer cells at the European Society for Molecular Oncology Congress here yesterday, representatives from CPCT and DRUP provided updates on the Phase I trials, which are digging into genomic features influencing treatment response and molecularly guided off-label drug matching in advanced cancers, respectively.

read article (free registration required)

Lung Cancer Studies Provide Contradictory Results on Utility of TMB as Biomarker for Treatment

(Precision Oncology News) Sept 29, 2019 - In presentations at the annual meeting of the European Society for Medical Oncology in Barcelona on Friday, researchers reported seemingly contradictory results on the utility of tumor mutational burden (TMB) as a biomarker for treatment of advanced non-small cell lung cancer (NSCLC) with pembrolizumab (Merck's Keytruda).

read article (free registration required)

Elevar Announces Results From The Angel Trial, A Study Of Monotherapy Rivoceranib (Apatinib) In Late-Stage Gastric Cancer Patients

(Elevar Therapeutics) Sept 29, 2019 - Elevar Therapeutics announced data from the ANGEL trial, a randomized phase 3 study of rivoceranib (also known as apatinib) plus best supportive care in patients with gastric or gastroesophageal junction cancer who have failed at least 2 prior lines of therapy.

read corporate press release

Immunomedics Provides Corporate Update

(Immunomedics) Sept 28, 2019 - Immunomedics today presented at the European Society for Medical Oncology (ESMO) Annual Congress interim data from the 100-patient cohort of cisplatin-eligible patients of the Company’s TROPHY-U-01 open-label Phase 2 study.

read corporate press release

TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer

(Yahoo! Finance) Sept 30, 2019 - Tyme Technologies, Inc. announced that its open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging overall (OS) results and has a well-tolerated safety profile.

read article

G1 Therapeutics Presents Updated Data At ESMO 2019 From Randomized Phase 2 Trial Of Trilaciclib In Combination With Chemotherapy In Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement In Overall Survival

(G1 Therapeutics) Sept 28, 2019 - G1 Therapeutics, Inc. today reported preliminary overall survival (OS) data from the company’s randomized Phase 2 trial of trilaciclib in combination with chemotherapy for the treatment of metastatic triple-negative breast cancer (mTNBC).

read corporate press release

G1 Therapeutics Presents First Clinical Data On Oral SERD G1T48 Demonstrating Safety And Tolerability In Patients With Advanced Breast Cancer At ESMO 2019

(G1 Therapeutics) Sept 29, 2019 - G1 Therapeutics, Inc. today announced preliminary results from a Phase 1/2a dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer.

read corporate press release

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

(Aileron) Sept 28, 2019 - Aileron Therapeutics announced the presentation of interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification at ESMO 2019 (Presentation Number: 475P).

read corporate press release

TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer

(Yahoo! Finance) Oct 1, 2019 - Study results demonstrate that oral SM-88 may play a clinically meaningful role in postponing use of hormonal castration in prostate cancer patients with rising prostate-specific antigen (PSA): More than 450,000 of these patient cases annually in the U.S. alone.

read article

Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO

(Yahoo! Finance) Oct 1, 2019 - Trovagene, Inc. today announced the presentation of its Phase 1b/2 trial evaluating onvansertib in combination with FOLFIRI and Avastin® (bevacizumab) in patients with KRAS-mutated metastatic Colorectal Cancer (mCRC).

read article

Genocea Announces Poster Presentation At The European Society For Medical Oncology (ESMO) Congress 2019 In Barcelona And Presentation At An Upcoming Investor Conference

(Genocea Biosciences) Sept 27, 2019 - Genocea Biosciences, Inc. today announced a poster presentation highlighting additional interim clinical results from its ongoing Phase 1/2a trial for GEN-009, the company’s neoantigen vaccine candidate driven by the ATLAS™ platform, at ESMO 2019.

read corporate press release

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

(Markets Insider) Sept 30, 2019 - Transgene today presented promising safety and efficacy data of TG4001 in combination with avelumab (BAVENCIO®), a human anti-programmed death ligand (PD-L1) antibody, in HPV-16+ recurrent or metastatic malignancies (including oropharyngeal cancers).

read article

Positive Data from Trovagene Phase 1b/2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference

(Yahoo! Finance) Sept 30, 2019 - Trovagene, Inc. today announced that results from the Company's Phase 1b/2 study of onvansertib in patients with relapsed/refractory acute myeloid leukemia (AML) were presented in an oral plenary session at ESMO 2019.

read article

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

(Xconomy National) Oct 1, 2019 - The European Society for Medical Oncology meeting has wrapped up in Barcelona, the last major clinical cancer conference until December’s annual ASH meeting for blood diseases. We’ve highlighted a few top stories for you.

read article
Next Page